Literature DB >> 8261439

GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.

F Helling1, A Shang, M Calves, S Zhang, S Ren, R K Yu, H F Oettgen, P O Livingston.   

Abstract

Cell surface gangliosides show altered patterns of expression as a consequence of malignant transformation and have therefore been of interest as potential targets for immunotherapy, including vaccine construction. One obstacle has been that some of the gangliosides that are overexpressed in human cancers are poorly immunogenic in humans. A case in point is GD3, a prominent ganglioside of human malignant melanoma. Using an approach that has been effective in the construction of bacterial carbohydrate vaccines, we have succeeded in increasing the immunogenicity of GD3 in the mouse by conjugating the ganglioside with immunogenic carriers. Several conjugation methods were used. The optimal procedure involved ozone cleavage of the double bond of GD3 in the ceramide backbone, introducing an aldehyde group, and coupling to aminolysyl groups of proteins by reductive amination. Conjugates were constructed with a synthetic multiple antigenic peptide expressing repeats of a malarial T-cell epitope, outer membrane proteins of Neisseria meningitidis, cationized bovine serum albumin, keyhole limpet hemocyanin, and polylysine. Mice immunized with these conjugates showed a stronger antibody response to GD3 than mice immunized with unconjugated GD3. The strongest response was observed in mice immunized with the keyhole limpet hemocyanin conjugate of the GD3 aldehyde derivative and the adjuvant QS-21. These mice showed not only a long-lasting high-titer IgM response but also a consistent high-titer IgG response (predominantly IgG1), indicating recruitment of T-cell help, although the titers of IgM and IgG antibodies following booster immunizations were not as high as they are in the response to classical T-cell-dependent antigens. This method is applicable to other gangliosides, and it may be useful in the construction of immunogenic ganglioside vaccines for the immunotherapy of human cancers expressing gangliosides on their cell surface.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8261439

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

Review 1.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

2.  Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

Authors:  Govind Ragupathi; Payal Damani; Kai Deng; Michelle M Adams; Jianfeng Hang; Constantine George; Philip O Livingston; David Y Gin
Journal:  Vaccine       Date:  2010-05-05       Impact factor: 3.641

3.  Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines.

Authors:  Qian Qin; Zhaojun Yin; Philip Bentley; Xuefei Huang
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

4.  Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Authors:  Kai Deng; Michelle M Adams; Payal Damani; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

Review 5.  Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues.

Authors:  P O Livingston; G Ragupathi; C Musselli
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

6.  The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family.

Authors:  M Peyrard; E Seroussi; A C Sandberg-Nordqvist; Y G Xie; F Y Han; I Fransson; J Collins; I Dunham; M Kost-Alimova; S Imreh; J P Dumanski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

7.  Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.

Authors:  V Kudryashov; P W Glunz; L J Williams; S Hintermann; S J Danishefsky; K O Lloyd
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

8.  Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Authors:  Brian H Kushner; Irene Y Cheung; Shakeel Modak; Kim Kramer; Govind Ragupathi; Nai-Kong V Cheung
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

9.  Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Authors:  K Kitamura; P O Livingston; S R Fortunato; E Stockert; F Helling; G Ritter; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.

Authors:  S Adluri; F Helling; S Ogata; S Zhang; S H Itzkowitz; K O Lloyd; P O Livingston
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.